Sigrid enters strategic partnership with GetHealthy to meet growing US demand for Glucose Stabiliser as non-pharmaceutical solution to blood sugar management

• US clinical nutrition for diabetes care market predicted to reach USD 2 billion by 2030[1]
• GetHealthy.store provides practice-focused ecommerce solutions to US physicians
• Taking Glucose Stabiliser pre-meal capsules prevents glucose spikes and provides sustained defense
• Ideal for managing blood sugar fluctuations and supporting balanced glucose levels
• Users report reduced bloating, increased energy levels and other significant health benefits – without any reduction in muscle mass

Stockholm, September 2nd, 2024: Sigrid Therapeutics today announced the signing of a strategic partnership with GetHealthy.store the leading US provider of practice-focused ecommerce solutions for healthcare and nutritional products. The partnership aims to meet growing demand for Sigrid’s Glucose Stabiliser which offers a game changing non-pharmaceutical solution to sustained blood sugar management. Since its initial trial launch in Florida earlier this year, Glucose Stabiliser is already loved by 1000s of customers, with users reporting reduced bloating, increased energy levels and other significant health benefits – with no reduction in muscle mass. This follows similar success in the Nordics and UK.

Glucose Stabiliser capsules work by using Sigrid’s patented SiPore® silica to slow down carbohydrate digestion. Silica is a natural GRAS[2]-certified material. Taken orally pre-meal Glucose Stabiliser thus provides an effective non-pharmaceutical defense against glucose spikes.

GetHealthy provides physicians with 360° ecommerce solutions based on an online storefront with product listings, escript protocols and educational materials backed by marketing support and warehousing and fulfillment. The company has established a leading position in the US supplement market with clients reporting up to 150% sales increases year after year.

Jon Armstrong, CEO of GetHealthy, sees enormous potential for Glucose Stabiliser: “We are delighted to enter this partnership with Sigrid to offer Glucose Stabiliser to our wide network of functional medicine practitioners. We see it as a true game changer and have already received incredibly positive feedback from the market. The solid science, safety profile, efficacy and ease of use make Glucose Stabiliser an ideal product for our clients to sell through the practice-owned ecommerce stores we provide to practices.“

Sana Alajmovic, CEO of Sigrid Therapeutics, states: “We were immediately impressed with the professionalism of John and the GetHealthy team and the way their ambition matched Sigrid’s. We believe this partnership with one of the leading e-commerce solutions provider in the US, will enable Glucose Stabiliser to fully realize its potential to make a lasting difference to the lives of anyone looking to actively control their glucose levels. This includes not only already diagnosed Type 2 diabetics and Impaired Glucose Tolerance patients, but also prediabetics and others with weight issues.”

Prof. Tore Bengtsson, CSO of Sigrid Therapeutics adds: “Glucose Stabiliser with its SiPore® technology offers a unique non-pharmaceutical alternative to injectable drugs for sustainable blood sugar management, curbs hunger sensations, and reduces bloating. We are excited about the prospect of Glucose Stabiliser being a gentler and safer way of achieving sustainable weight control without negative side effects on lean body mass. For patients who discontinue treatment with injectable drugs Glucose Stabiliser could be a way to safeguard against the common weight regain that follows stopping such treatments.”

For more information, please contact:

Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics
Phone: +46 72 3893396
Email: sana@sigridthx.com

RHA Communications

Ola@rhacomms.eu / Richard@rhacomms.eu

About GetHealthy

GetHealthy offers an all-in-one digital ecommerce platform designed to empower healthcare practitioners and increase revenue. Their comprehensive suite of services, including diagnostic tests, premium supplements, and turnkey business solutions, simplifies the management of online sales and enhances patient care. With a user-friendly interface and dedicated support, GetHealthy bridges the gap between technology and care, enabling practitioners to focus on providing exceptional wellness outcomes while growing their practice efficiently and effectively. https://gethealthy.store/

About Mesoporous silica particles (MSPs)

Mesoporous silica particles (MSPs) are a type of ingestible, synthetic, amorphous silica particle that can be produced with a large surface area and a range of pore sizes. Studies in mice, published in Nanomedicine1,2,have shown that food efficiency was reduced by 33% leading to a positive effect on metabolic profile with significantly lower levels of adipose tissue formation and leptin, together with lower levels of circulating insulin. Weight gain was thus sufficiently attenuated. Additional pre-clinical results published in Advanced Healthcare Materials3 showed that these findings are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSPs resulting in an enzyme-blocking effect which reduces the breakdown of food and thus reduces the energy uptake into the body. This mode of action was further confirmed in vivo when MSPs added to milk led to reduced lipid absorption compared to a control4.

About Sigrid Therapeutics

Sigrid Therapeutics (Sigrid) is a clinical-stage, consumer focused healthtech company pioneering a new class of engineered materials to prevent and treat metabolic diseases and disorders, including type 2 diabetes. The Company’s lead product, SiPore21®, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore®. Designed to act locally in the gut, SiPore21® consists of precisely engineered, micron-sized mesoporous silica particles (MSPs) with tailored porosity. Clinical data confirms the beneficial effects of SiPore® technology on a range of metabolic parameters and its excellent safety profile3-7. SiPore21® benefits from a unique mode of action, employing  mechanical entrapment of amylase and lipase within its porous structure. This physically hinders the interaction of digestive enzymes with food, effectively reducing the breakdown of carbohydrates and fats8. SiPore21® is being developed as the first oral medical device for blood sugar control in people at risk of developing type 2 diabetes. https://www.sigridthx.com/.

References

1. Large pore mesoporous silica induced weight loss in obese mice, Nanomedicine, 2014,

https://www.futuremedicine.com/doi/10.2217/nnm.13.138.

2. Mesoporous Silica with Precisely Controlled Pores Reduces Food Efficiency and Suppresses Weight Gain in Mice, Nanomedicine, 2020, https://www.futuremedicine.com/doi/10.2217/nnm-2019-0262.
3. Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces

Metabolic Risk Factors in Humans, Advanced Healthcare Materials, 2020, https://doi.org/10.1002/adhm.202000057.

4. Towards mesoporous silica as a pharmaceutical treatment for obesity - impact on lipid digestion and absorption, European Journal of Pharmaceutics and Biopharmaceutics, 2022, https://doi.org/10.1016/j.ejpb.2022.02.001.
5. Oral intake of mesoporous silica is safe and well tolerated in male humans, PLoS ONE, 2020, DOI: 10.1002/adhm.202000057. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240030
6. Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics, Nanomedicine, 2021,

https://doi.org/10.2217/nnm-2021-0235.

7. Mesoporous Silica Particles Retain their Structure and Function While Passing Through the Gastrointestinal Tracts of Mice and Humans, ACS Applied Materials & Interfaces, 2023, https://doi.org/10.1021/acsami.2c16710.
8. Activity and Stability of Nanoconfined Alpha-Amylase in Mesoporous Silica ACS MATERIAL Au, 2023, https://doi.org/10.1021/acsmaterialsau.3c00028. Publication date: August 4, 2023.